Pharmacological conversion of atrial fibrillation in the patients of Graves' disease

Yo Kunii, Takashi Uruno, Masako Matsumoto, Koji Mukasa, Jaeduk Noh, Koichi Ito, Makoto Akaishi, Shingo Hori, Hiroe Nakazawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Hyperthyroidism is one of the common causes of atrial fibrillation (AF), and AF is associated with increased morbidity and mortality due to thromboembolism. The sinus rhythm maintenance rate of hyperthyroidism- induced AF patients after conversion to sinus rhythm is excellent. The present study was undertaken to assess the efficacy and safety of bepridil, a multichannel blocker, in patients with hyperthyroidism-induced persistent AF. Methods and Results: Sixty-two patients with hyperthyroidism-induced persistent AF were treated with bepridil. Oral bepridil therapy resulted in conversion to sinus rhythm in 32 (51.6%) of the 62 patients. There were no significant differences in clinical characteristics between the responders and non-responders. At the observation period of an average of 23.9 months, the sinus rhythm maintenance rate was found to be 81.3%. Adverse effects consisted of abnormal QTc prolongation in 3 patients and sinus bradycardia in 10 patients. There was one death in which a causal association with bepridil could not be ruled out. Conclusions: Bepridil is as beneficial treatment to convert AF for the patients with hyperthyroidism-induced persistent AF as it is for the patients with AF due to other causes. However, bepridil should be used with caution to avoid serious side effects.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalTokai Journal of Experimental and Clinical Medicine
Volume37
Issue number4
Publication statusPublished - 2012 Dec

Fingerprint

Bepridil
Graves Disease
Atrial Fibrillation
Pharmacology
Hyperthyroidism
Maintenance
Thromboembolism
Bradycardia
Observation
Morbidity
Safety
Mortality
Therapeutics

Keywords

  • Atrial fibrillation (AF)
  • Bepridil
  • Cardioversion
  • Graves' disease
  • Hyperthyroidism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kunii, Y., Uruno, T., Matsumoto, M., Mukasa, K., Noh, J., Ito, K., ... Nakazawa, H. (2012). Pharmacological conversion of atrial fibrillation in the patients of Graves' disease. Tokai Journal of Experimental and Clinical Medicine, 37(4), 107-112.

Pharmacological conversion of atrial fibrillation in the patients of Graves' disease. / Kunii, Yo; Uruno, Takashi; Matsumoto, Masako; Mukasa, Koji; Noh, Jaeduk; Ito, Koichi; Akaishi, Makoto; Hori, Shingo; Nakazawa, Hiroe.

In: Tokai Journal of Experimental and Clinical Medicine, Vol. 37, No. 4, 12.2012, p. 107-112.

Research output: Contribution to journalArticle

Kunii, Y, Uruno, T, Matsumoto, M, Mukasa, K, Noh, J, Ito, K, Akaishi, M, Hori, S & Nakazawa, H 2012, 'Pharmacological conversion of atrial fibrillation in the patients of Graves' disease', Tokai Journal of Experimental and Clinical Medicine, vol. 37, no. 4, pp. 107-112.
Kunii, Yo ; Uruno, Takashi ; Matsumoto, Masako ; Mukasa, Koji ; Noh, Jaeduk ; Ito, Koichi ; Akaishi, Makoto ; Hori, Shingo ; Nakazawa, Hiroe. / Pharmacological conversion of atrial fibrillation in the patients of Graves' disease. In: Tokai Journal of Experimental and Clinical Medicine. 2012 ; Vol. 37, No. 4. pp. 107-112.
@article{9123b6de28504cd69a2ef916356fd9bb,
title = "Pharmacological conversion of atrial fibrillation in the patients of Graves' disease",
abstract = "Background: Hyperthyroidism is one of the common causes of atrial fibrillation (AF), and AF is associated with increased morbidity and mortality due to thromboembolism. The sinus rhythm maintenance rate of hyperthyroidism- induced AF patients after conversion to sinus rhythm is excellent. The present study was undertaken to assess the efficacy and safety of bepridil, a multichannel blocker, in patients with hyperthyroidism-induced persistent AF. Methods and Results: Sixty-two patients with hyperthyroidism-induced persistent AF were treated with bepridil. Oral bepridil therapy resulted in conversion to sinus rhythm in 32 (51.6{\%}) of the 62 patients. There were no significant differences in clinical characteristics between the responders and non-responders. At the observation period of an average of 23.9 months, the sinus rhythm maintenance rate was found to be 81.3{\%}. Adverse effects consisted of abnormal QTc prolongation in 3 patients and sinus bradycardia in 10 patients. There was one death in which a causal association with bepridil could not be ruled out. Conclusions: Bepridil is as beneficial treatment to convert AF for the patients with hyperthyroidism-induced persistent AF as it is for the patients with AF due to other causes. However, bepridil should be used with caution to avoid serious side effects.",
keywords = "Atrial fibrillation (AF), Bepridil, Cardioversion, Graves' disease, Hyperthyroidism",
author = "Yo Kunii and Takashi Uruno and Masako Matsumoto and Koji Mukasa and Jaeduk Noh and Koichi Ito and Makoto Akaishi and Shingo Hori and Hiroe Nakazawa",
year = "2012",
month = "12",
language = "English",
volume = "37",
pages = "107--112",
journal = "Tokai Journal of Experimental and Clinical Medicine",
issn = "0385-0005",
publisher = "Tokai Medical Association",
number = "4",

}

TY - JOUR

T1 - Pharmacological conversion of atrial fibrillation in the patients of Graves' disease

AU - Kunii, Yo

AU - Uruno, Takashi

AU - Matsumoto, Masako

AU - Mukasa, Koji

AU - Noh, Jaeduk

AU - Ito, Koichi

AU - Akaishi, Makoto

AU - Hori, Shingo

AU - Nakazawa, Hiroe

PY - 2012/12

Y1 - 2012/12

N2 - Background: Hyperthyroidism is one of the common causes of atrial fibrillation (AF), and AF is associated with increased morbidity and mortality due to thromboembolism. The sinus rhythm maintenance rate of hyperthyroidism- induced AF patients after conversion to sinus rhythm is excellent. The present study was undertaken to assess the efficacy and safety of bepridil, a multichannel blocker, in patients with hyperthyroidism-induced persistent AF. Methods and Results: Sixty-two patients with hyperthyroidism-induced persistent AF were treated with bepridil. Oral bepridil therapy resulted in conversion to sinus rhythm in 32 (51.6%) of the 62 patients. There were no significant differences in clinical characteristics between the responders and non-responders. At the observation period of an average of 23.9 months, the sinus rhythm maintenance rate was found to be 81.3%. Adverse effects consisted of abnormal QTc prolongation in 3 patients and sinus bradycardia in 10 patients. There was one death in which a causal association with bepridil could not be ruled out. Conclusions: Bepridil is as beneficial treatment to convert AF for the patients with hyperthyroidism-induced persistent AF as it is for the patients with AF due to other causes. However, bepridil should be used with caution to avoid serious side effects.

AB - Background: Hyperthyroidism is one of the common causes of atrial fibrillation (AF), and AF is associated with increased morbidity and mortality due to thromboembolism. The sinus rhythm maintenance rate of hyperthyroidism- induced AF patients after conversion to sinus rhythm is excellent. The present study was undertaken to assess the efficacy and safety of bepridil, a multichannel blocker, in patients with hyperthyroidism-induced persistent AF. Methods and Results: Sixty-two patients with hyperthyroidism-induced persistent AF were treated with bepridil. Oral bepridil therapy resulted in conversion to sinus rhythm in 32 (51.6%) of the 62 patients. There were no significant differences in clinical characteristics between the responders and non-responders. At the observation period of an average of 23.9 months, the sinus rhythm maintenance rate was found to be 81.3%. Adverse effects consisted of abnormal QTc prolongation in 3 patients and sinus bradycardia in 10 patients. There was one death in which a causal association with bepridil could not be ruled out. Conclusions: Bepridil is as beneficial treatment to convert AF for the patients with hyperthyroidism-induced persistent AF as it is for the patients with AF due to other causes. However, bepridil should be used with caution to avoid serious side effects.

KW - Atrial fibrillation (AF)

KW - Bepridil

KW - Cardioversion

KW - Graves' disease

KW - Hyperthyroidism

UR - http://www.scopus.com/inward/record.url?scp=84871569823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871569823&partnerID=8YFLogxK

M3 - Article

C2 - 23238902

AN - SCOPUS:84871569823

VL - 37

SP - 107

EP - 112

JO - Tokai Journal of Experimental and Clinical Medicine

JF - Tokai Journal of Experimental and Clinical Medicine

SN - 0385-0005

IS - 4

ER -